A new study in mice found that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission. This approach shows such promise that it’s already being tested in an ongoing clinical trial in people with advanced bladder cancer.
This finding, led by William Kim, MD, professor of medicine in the division of oncology and member of the Lineberger Comprehensive Cancer Center, was published August 16 in the Journal of Clinical Investigation. and featured August 20 in Oncology Times.
“Bladder cancer rates in the United States have been stable or decreasing slightly over the past decade, but five-year survival rates have barely budged since the 1990s,” said Kim, the Rush S. Dickson Distinguished Professor of Medicine and professor of Genetics and the paper’s co-corresponding author. “Hence our search for ways to improve treatments for a cancer that can be extremely difficult to treat in its advanced stages.”
Read more from the Lineberger Comprehensive Cancer Center Newsroom.